(GIVN) Givaudan - Ratings and Ratios
Fragrance, Beauty, Taste, Flavour, Ingredients, Supplements, Confectionery
Description: GIVN Givaudan
Givaudan SA is a leading global player in the consumer goods industry, providing a wide range of products and services in fragrance, beauty, taste, and wellbeing. The companys two divisions, Fragrance & Beauty and Taste & Wellbeing, cater to diverse customer needs, from fine fragrances and personal care products to beverages, dairy products, and confectionery.
With a rich history dating back to 1796, Givaudan has established itself as a trusted partner for many consumer goods companies worldwide. Its global presence spans across multiple regions, including Europe, North America, Latin America, Asia Pacific, Africa, and the Middle East, allowing it to tap into various markets and capitalize on growth opportunities.
From a financial perspective, Givaudans market capitalization stands at approximately CHF 35.7 billion, with a return on equity (RoE) of 47.14%, indicating a strong ability to generate profits from shareholder equity. The companys forward price-to-earnings (P/E) ratio is around 29.41, suggesting that the market expects continued growth and is willing to pay a premium for its shares. Additionally, Givaudans dividend yield and payout ratio are worth examining to assess its ability to return value to shareholders.
To further evaluate Givaudans performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin can be analyzed. For instance, the companys revenue growth rate, both historically and forecasted, can provide insights into its ability to expand its customer base and increase sales. Moreover, examining Givaudans gross margin and operating margin can help assess its pricing power, cost management, and operational efficiency.
Other relevant KPIs for Givaudan include its debt-to-equity ratio, interest coverage ratio, and cash conversion cycle, which can provide a more comprehensive understanding of the companys financial health and managements ability to allocate capital effectively. By analyzing these metrics, investors and analysts can gain a deeper understanding of Givaudans strengths, weaknesses, and potential areas for improvement.
GIVN Stock Overview
| Market Cap in USD | 39,830m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
GIVN Stock Ratings
| Growth Rating | -20.7% |
| Fundamental | 83.6% |
| Dividend Rating | 51.0% |
| Return 12m vs S&P 500 | -32.9% |
| Analyst Rating | - |
GIVN Dividends
| Dividend Yield 12m | 1.93% |
| Yield on Cost 5y | 2.03% |
| Annual Growth 5y | 1.86% |
| Payout Consistency | 97.3% |
| Payout Ratio | 40.7% |
GIVN Growth Ratios
| Growth Correlation 3m | -96.1% |
| Growth Correlation 12m | -54.1% |
| Growth Correlation 5y | 15.9% |
| CAGR 5y | -0.49% |
| CAGR/Max DD 5y | -0.01 |
| Sharpe Ratio 12m | -0.82 |
| Alpha | -23.46 |
| Beta | 0.078 |
| Volatility | 22.94% |
| Current Volume | 12.7k |
| Average Volume 20d | 16.4k |
| Stop Loss | 3268.9 (-3%) |
| Signal | -1.53 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (2.13b TTM) > 0 and > 6% of Revenue (6% = 879.4m TTM) |
| FCFTA 0.20 (>2.0%) and ΔFCFTA 14.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.40% (prev 16.30%; Δ -6.90pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 2.79b > Net Income 2.13b (YES >=105%, WARN >=100%) |
| Net Debt (4.00b) to EBITDA (2.46b) ratio: 1.63 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.49 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (9.27m) change vs 12m ago 0.30% (target <= -2.0% for YES) |
| Gross Margin 42.53% (prev 37.77%; Δ 4.76pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 124.2% (prev 92.55%; Δ 31.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 11.25 (EBITDA TTM 2.46b / Interest Expense TTM 171.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.71
| (A) 0.11 = (Total Current Assets 4.21b - Total Current Liabilities 2.83b) / Total Assets 12.10b |
| (B) 0.58 = Retained Earnings (Balance) 6.97b / Total Assets 12.10b |
| (C) 0.16 = EBIT TTM 1.92b / Avg Total Assets 11.80b |
| (D) 0.94 = Book Value of Equity 7.06b / Total Liabilities 7.52b |
| Total Rating: 4.71 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.64
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 6.67% = 3.34 |
| 3. FCF Margin 16.19% = 4.05 |
| 4. Debt/Equity 0.96 = 2.06 |
| 5. Debt/Ebitda 1.78 = 0.43 |
| 6. ROIC - WACC 12.38% = 12.50 |
| 7. RoE 50.54% = 2.50 |
| 8. Rev. Trend 72.95% = 3.65 |
| 9. Rev. CAGR 5.07% = 0.63 |
| 10. EPS Trend 39.22% = 0.98 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of GIVN shares?
Over the past week, the price has changed by -1.75%, over one month by -3.69%, over three months by -18.36% and over the past year by -21.53%.
Is Givaudan a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GIVN is around 3096.28 CHF . This means that GIVN is currently overvalued and has a potential downside of -8.12%.
Is GIVN a buy, sell or hold?
What are the forecasts/targets for the GIVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4134.4 | 22.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 3360.7 | -0.3% |
GIVN Fundamental Data Overview
Market Cap CHF = 31.93b (31.93b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 762.0m CHF (Cash And Short Term Investments, last quarter)
P/E Trailing = 29.2898
P/E Forward = 25.7069
P/S = 4.2357
P/B = 7.5843
P/EG = 4.148
Beta = 0.533
Revenue TTM = 14.66b CHF
EBIT TTM = 1.92b CHF
EBITDA TTM = 2.46b CHF
Long Term Debt = 3.56b CHF (from longTermDebt, last quarter)
Short Term Debt = 819.0m CHF (from shortTermDebt, last quarter)
Debt = 4.38b CHF (Calculated: Short Term 819.0m + Long Term 3.56b)
Net Debt = 4.00b CHF (from netDebt column, last quarter)
Enterprise Value = 35.55b CHF (31.93b + Debt 4.38b - CCE 762.0m)
Interest Coverage Ratio = 11.25 (Ebit TTM 1.92b / Interest Expense TTM 171.0m)
FCF Yield = 6.67% (FCF TTM 2.37b / Enterprise Value 35.55b)
FCF Margin = 16.19% (FCF TTM 2.37b / Revenue TTM 14.66b)
Net Margin = 14.51% (Net Income TTM 2.13b / Revenue TTM 14.66b)
Gross Margin = 42.53% ((Revenue TTM 14.66b - Cost of Revenue TTM 8.42b) / Revenue TTM)
Tobins Q-Ratio = 5.04 (Enterprise Value 35.55b / Book Value Of Equity 7.06b)
Interest Expense / Debt = 0.02% (Interest Expense 1.00m / Debt 4.38b)
Taxrate = 16.98% (from yearly Income Tax Expense: 223.0m / 1.31b)
NOPAT = 1.60b (EBIT 1.92b * (1 - 16.98%))
Current Ratio = 1.49 (Total Current Assets 4.21b / Total Current Liabilities 2.83b)
Debt / Equity = 0.96 (Debt 4.38b / last Quarter total Stockholder Equity 4.58b)
Debt / EBITDA = 1.78 (Net Debt 4.00b / EBITDA 2.46b)
Debt / FCF = 1.85 (Debt 4.38b / FCF TTM 2.37b)
Total Stockholder Equity = 4.21b (last 4 quarters mean)
RoA = 17.57% (Net Income 2.13b, Total Assets 12.10b )
RoE = 50.54% (Net Income TTM 2.13b / Total Stockholder Equity 4.21b)
RoCE = 24.75% (Ebit 1.92b / (Equity 4.21b + L.T.Debt 3.56b))
RoIC = 17.92% (NOPAT 1.60b / Invested Capital 8.91b)
WACC = 5.54% (E(31.93b)/V(36.31b) * Re(6.30%)) + (D(4.38b)/V(36.31b) * Rd(0.02%) * (1-Tc(0.17)))
Shares Correlation 5-Years: -60.0 | Cagr: -0.07%
Discount Rate = 6.30% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 79.74% ; FCFE base≈1.65b ; Y1≈1.83b ; Y5≈2.40b
Fair Price DCF = 4516 (DCF Value 41.68b / Shares Outstanding 9.23m; 5y FCF grow 12.72% → 3.0% )
Revenue Correlation: 72.95 | Revenue CAGR: 5.07%
Rev Growth-of-Growth: 1.29
EPS Correlation: 39.22 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 64.66